Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05032313 · ClinicalTrials.gov registry record
Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer
A clinical trial, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- 371
- Enrollment target
NCT05032313: Completed study, sponsored by Becton, Dickinson and Company.
NCT05032313 is a clinical trial that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 371 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05032313 has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- 371 participants
- Enrollment target
Study Summary
Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis.
Primary Outcome
Determine equivalence between the investigational OneFlow CLPD Limited Panel on FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal (T-cell, B-cell, and NK-cell) or Abnormal (T-cell or B-cell or NK-cell) phenotype using leftover, hematologically abnormal specimens . Sensitivity and specificity are calculated
Interventions
- DIAGNOSTIC_TEST IUO CLPD Limited Panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2023-12-29 |
What the finished NCT05032313 record still lists
NCT05032313 is an observational study that tracks outcomes without assigning an intervention. The registered 371 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which IUO CLPD Limited Panel is the first listed.
NCT05032313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05032313 about?
NCT05032313 is a clinical study titled "Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer". Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis.
What is the current status of trial NCT05032313?
This trial is currently completed. The enrollment target is 371 participants. The study started on 2021-04-26. Estimated completion is 2023-12-29.
What interventions are being tested in trial NCT05032313?
The interventions under investigation include: IUO CLPD Limited Panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05032313?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05743673 · 371 participants
SHAPE Test for Preoperative Risk Stratification
- NCT05761847 · 371 participants · NA
Pediatric Medication Therapy Management Trial
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI